According to two studies presented at a retina meeting, patients with macular edema related to retinal vein occlusion had significant improvement in vision when treated with ranibizumab (Lucentis) in each of two dosages. In trials including approximately 400 patients apiece, researchers from Johns Hopkins University and Houston's Methodist Hospital randomized patients to monthly 0.5 mg or 0.3 mg intravitreal injections of ranibizumab, or to sham injections, for six months. Notably, 46 to 47 percent of patients in both ranibizumab groups improved by at least 15 letters, compared with 16.9 percent of the control group.
10:03 AM
Keshav Bhat


